Adenosine
Product Images NDC 51662-1345

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Adenosine (NDC 51662-1345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (20 mL Carton)

A carton label for Adenosine Injection, USP 60 mg/20 mL (3 mg/mL) by Hospira. The label includes dosage form as a 20 mL single-dose vial, storage instructions, manufacturer details, a barcode, and usage notes indicating intravenous infusion only. The product is sterile and nonpyrogenic, manufactured in India for Hospira, Inc.*

FDA Label Image

Adverse Reactions 3 (Adverse Reaction 3)

A data table listing various disorders and associated conditions, potentially adverse reactions. Categories include Cardiac Disorders with conditions like cardiac arrest and atrial fibrillation; Gastrointestinal Disorders with nausea and vomiting; General Disorders including injection site pain; Immune System Disorders with hypersensitivity; Nervous System Disorders listing hemorrhage and seizures; and Respiratory Disorders including bronchospasm and throat tightness.*

FDA Label Image

Adverse Reactions 1 (Adverse Reactions 1)

A data table listing adverse reactions observed with Adenosine Injection in a study of 1,421 subjects, including flushing (44%), chest discomfort (40%), dyspnea (28%), headache (18%), throat/neck/jaw discomfort (15%), gastrointestinal discomfort (13%), lightheadedness/dizziness (12%), upper extremity discomfort (4%), ST segment depression (3%), first-degree AV block (3%), second-degree AV block (3%), paresthesia (2%), hypotension (2%), nervousness (2%), and arrhythmias (1%).*

FDA Label Image

Adverse Reactions 2 (Adverse Reactions 2)

Table presenting adverse effects of ADENOSINE grouped by body system. It includes symptoms in categories such as body as a whole, cardiovascular, respiratory, central nervous, genital/urinary, and special senses, listing specific conditions and symptoms for each system.*

FDA Label Image

D And A (D And A)

Data table presenting infusion rates in mL per minute over 6 minutes for total dose 0.84 mg/kg of ADENOSINE, correlated to patient weight in kilograms ranging from 45 to 90 kg.*

FDA Label Image

Logo (Logo)

FDA Label Image

Serialized Labeling (Serialized Product)

Box packaging for Adenosine Injection USP, 60 mg/20 mL (3 mg/mL) single-dose vial. The label includes dosage strength and volume with manufacturer and distributor information, HF Acquisition Co LLC DBA HealthFirst. The packaging also features a barcode and standard drug labeling details.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of adenosine, showing its molecular framework with rings and attached functional groups, including amine and hydroxyl groups.*

FDA Label Image

Vial Label (Vial Label)

Adenosine Injection USP 60 mg/20 mL (3 mg/mL) sterile single-dose vial label. The label states it is for intravenous infusion only, sterile, nonpyrogenic, and Rx only. Manufactured by Gland Pharma Limited, India, for Hospira, Inc., Lake Forest, IL. It contains adenosine and sodium chloride in water for injection with pH between 4.5 and 7.5. Storage instructions and warnings about crystallization are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.